Imaging Endpoints II LLC

1. Sage Therapeutics, Inc. $358,223 6 payments
2. Genzyme Corporation $277,492 36 payments
3. Ucb SA $222,662 4 payments
4. Eli Lilly and Company $138,276 3 payments
5. Genentech, Inc. $56,329 5 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $54,205 21 payments
7. Amgen Inc. $42,950 1 payment
8. UCB, Inc. $41,007 1 payment
9. Sun Pharmaceutical Industries Inc. $20,600 3 payments
10. Gilead Sciences, Inc. $15,425 1 payment

1. Study to Evaluate SAGE-324 in Participants With Essential Tremors $214,946 3 payments
2. A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinsons Disease $199,400 4 payments
3. A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor $143,277 3 payments
4. A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of Ly3314814 in Mild Alzheimers Disease Dementia $138,276 3 payments
5. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $124,138 11 payments
6. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $117,245 23 payments
7. A Multicenter Phase 2, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Ucb0022 in Study Participants With Advanced Parkinson's Disease $64,269 1 payment
8. A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Tak-071 in Parkinson Disease Patients With Cognitive Impairment and An Elevated Risk of Falls $54,205 21 payments
9. Prodromal to Mild Ad $46,329 4 payments
10. A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis $42,950 1 payment

1. Overhead $11,900 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.